Answers are grounded in this paper and cite their sources.
Expression of monoamine oxidase type B (MAO-B) in brain increases with aging, and is further increased in Alzheimer's disease (AD). This up-regulation of MAO-B has been suggested to contribute to neurodegenerative processes by increasing oxidative stress, prompting development of MAO-B inhibitors (MAO-Bi) in treatment of AD. Evidence of clinical efficacy comes from unpublished data on lazabemide, a selective MAO-Bi previously developed by Roche that significantly improved cognition and functionality in AD patients. RO4602522 is a potent and selective MAO-Bi which is currently tested in a phase 2 AD patient study (“MAyflOwer RoAD”). Simulations based on earlier PK/MAO-B inhibition data from young healthy subjects predicted that maximal enzyme inhibition in hippocampus (median of 84%) would be approached in AD patients at 1mg (median of 80%), assuming no relevant effect of age and disease on PK/PD relationship. This PET study is undertaken to confirm high level MAO-B occupancy at the doses tested in “MAyflOwer RoAD” study, and to characterize the PK/MAO-B inhibition relationship in AD patients. Results of 1mg and 0.2mg groups are presented. After signing informed consent, 6 AD patients and 6 elderly controls (ECs) were administered 1mg RO4602522 for 2 weeks, or a 5mg dose followed by 0.2mg doses for 6 days. PET scans for MAO-B occupancy were performed at baseline and 24h postdose at steady-state, using [11 C]-L-deprenyl-D2 tracer. Five AD patients (2 at 1mg, 3 at 0.2mg), MMSE 17–26 and 6 ECs (3 at 1mg, 3 at 0.2mg) underwent pre and postdose PET scans. At 1mg doses, MAO-B occupancy ranged from 71%-88%, across subjects and brain regions of interest, with a trend for higher occupancy in subcortical regions. Occupancies in 0.2mg group ranged from 37–83%, and were very sensitive to plasma concentrations. Plots of MAO-B occupancy vs concentration showed a sharp increase at low concentrations, to a plateau in MAO-B occupancy (Figure 1), as predicted from the model in young subjects. Data in AD patients and ECs were well predicted by the model generated with enzyme occupancy data from young subjects, and showed that near-maximal inhibition of brain MAO-B was achieved with 1mg RO4606522 daily, regardless of the population. Relationship between plasma concentration and MAO-B inhibition in hippocampus of AD patients and elderly controls in steady-state conditions at 0.2mg and 1mg RO4602522 (note: MAO-B inhibition in hippocampus (81.1%) for third AD patient at 0.2 mg not reflected in this plot as corresponding plasma concentration was not available)
No takes yet. Share an insight, caveat, or question.
Ricci et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: